Payment overview · 2025
General Payments
$1,741.48
82 reported records · 13 companies
Healthcare provider profile · identity verified
Jonathan P Martinez, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PALMDALE, CA · NPI 1679764450
Verified facts
What the public records show
CMS Open Payments records show Jonathan P Martinez, D.O. received $1,741.48 in general payments during 2025 across 82 reported records.
ViiV Healthcare Company accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Jardiance, Rexulti, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Biktarvy by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $629.15 | 36.1% | 23 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $374.79 | 21.5% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.49 | 12.0% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $179.58 | 10.3% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.50 | 4.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $72.67 | 4.2% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $44.32 | 2.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.23 | 2.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $34.87 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.71 | 1.6% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $22.41 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.12 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.64 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,741.48 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $437.55 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $179.66 | 12 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $131.51 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $128.86 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.71 | 6 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $72.67 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.23 | 4 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $48.64 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $36.12 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $12.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 193 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 71 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 102 |
| Metformin Hcl | Metformin Hcl | 228 | 77 |
| Losartan Potassium | Losartan Potassium | 215 | 68 |
| Gabapentin | Gabapentin | 204 | 76 |
| Jardiance | Empagliflozin | 193 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 61 |
| Omeprazole | Omeprazole | 159 | 64 |
| Meloxicam | Meloxicam | 155 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 51 |
| Lisinopril | Lisinopril | 152 | 52 |
| Ibuprofen | Ibuprofen | 141 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 45 |
| Montelukast Sodium | Montelukast Sodium | 100 | 35 |
| Glipizide | Glipizide | 95 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 34 |
| Rybelsus | Semaglutide | 82 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 25 |
| Mirtazapine | Mirtazapine | 74 | 28 |
| Trazodone Hcl | Trazodone Hcl | 67 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 32 |
| Benazepril Hcl | Benazepril Hcl | 64 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 26 |
| Furosemide | Furosemide | 58 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 22 |
| Finasteride | Finasteride | 45 | 20 |
| Allopurinol | Allopurinol | 44 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 18 |
| Latanoprost | Latanoprost | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Carvedilol | Carvedilol | 37 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Alendronate Sodium | Alendronate Sodium | 35 | 13 |
| Simvastatin | Simvastatin | 35 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Famotidine | Famotidine | 29 | 13 |
| Nifedipine Er | Nifedipine | 29 | 12 |
| Topiramate | Topiramate | 29 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Tivicay | Dolutegravir Sodium | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | 11 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Baclofen | Baclofen | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Vivitrol | Naltrexone Microspheres | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 11 | suppressed |
| Etravirine | Etravirine | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Maraviroc | Maraviroc | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,741.48 · 82 records | ViiV Healthcare Company | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ACCRUFER, AIRSUPRA, APRETUDE, AUSTEDO XR, BRIXADI, Biktarvy, CABENUVA, CAPVAXIVE, COBENFY, DOVATO, JARDIANCE, Ozempic, PIFELTRO, REXULTI, RUKOBIA, Rybelsus, SUBLOCADE, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error